Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Belada, David ^{[2
]}

Sureda, Anna ^{[3
]}

Leppa, Sirpa ^{[4
,5
]}

Vermaat, Joost S. P. ^{[6
]}

Holte, Harald ^{[7
,8
]}

Hutchings, Martin ^{[9
]}

Lugtenburg, Pieternella ^{[10
]}

de Vos, Sven ^{[11
]}

Abrisqueta, Pau ^{[12
]}

Nijland, Marcel ^{[13
,14
]}

Christensen, Jacob Haaber ^{[15
]}

Wahlin, Bjorn E. ^{[16
]}

Linton, Kim M. ^{[17
,18
]}

Wang, Liwei ^{[19
]}

Abbas, Aqeel ^{[19
]}

Rana, Ali ^{[19
]}

Quadri, Syed ^{[20
]}

Falchi, Lorenzo ^{[21
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[3] Univ Barcelona, Inst Catala Oncol, Hosp Duran Reynals, IDIBELL, Lhospitalet De Llobregat, Spain

[4] Univ Helsinki, Helsinki, Finland

[5] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[6] Leiden Univ, Med Ctr, Leiden, Netherlands

[7] Oslo Univ Hosp, Oslo, Norway

[8] KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[9] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[10] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[11] Ronald Reagan Univ Calif, Los Angeles Med Ctr, Los Angeles, CA USA

[12] Hosp Univ Vall Hebron, Barcelona, Spain

[13] Univ Med Ctr Groningen, Groningen, Netherlands

[14] Univ Groningen, Groningen, Netherlands

[15] Odense Univ Hosp, Odense, Denmark

[16] Karolinska Inst, Stockholm, Sweden

[17] Christie NHS Fdn Trust, Manchester, Lancs, England

[18] Manchester Canc Res Ctr, Manchester, Lancs, England

[19] Genmab, Princeton, NJ USA

[20] AbbVie, N Chicago, IL USA

[21] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; bispecific; follicular lymphoma; hematologic malignancy; non-Hodgkin lymphoma; phase I/II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-474

引用

页码：S454 / S454

页数：1

共 50 条

[1] Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
Merryman, Reid
Belada, David
Sureda, Anna
Leppa, Sirpa
Vermaat, Joost S. P.
Holte, Harald
Hutchings, Martin
Lugtenburg, Pieternella
de Vos, Sven
Abrisqueta, Pau
Nijland, Marcel
Christensen, Jacob Haaber
Wahlin, Bjorn E.
Linton, Kim M.
Wang, Liwei
Abbas, Aqeel
Rana, Ali
Quadri, Syed
Falchi, Lorenzo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
Sortais, Clara
Lok, Anne
Tessoulin, Benoit
Gastinne, Thomas
Mahe, Beatrice
Dubruille, Viviane
Blin, Nicolas
Touzeau, Cyrille
Moreau, Anne
Bossard, Celine
Peterlin, Pierre
Garnier, Alice
Guillaume, Thierry
Le Bourgeois, Amandine
Chevallier, Patrice
Moreau, Philippe
Leux, Christophe
Le Gouill, Steven
ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1595 - 1604
[3] Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
Clara Sortais
Anne Lok
Benoit Tessoulin
Thomas Gastinne
Béatrice Mahé
Viviane Dubruille
Nicolas Blin
Cyrille Touzeau
Anne Moreau
Céline Bossard
Pierre Peterlin
Alice Garnier
Thierry Guillaume
Amandine Le Bourgeois
Patrice Chevallier
Philippe Moreau
Christophe Leux
Steven Le Gouill
Annals of Hematology, 2020, 99 : 1595 - 1604
[4] Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma
Wu, Wei
Bruscaggin, Alessio
Valera, Alexandra
Flospergher, Elena
Bonfiglio, Ferdinando
Spina, Valeria
Terzi-Di-Bergamo, Lodovico
Moccia, Alden
Moia, Riccardo
Ruffini, Alessia
Stathis, Anastasios
Faderl, Martin
Koch, Ricardo
Forestieri, Gabriela
Pini, Katia
Condoluci, Adalgisa
Pirosa, Maria Cristina
Gerber, Bernhard
Gillessen, Silke
Stussi, Georg
Ghielmini, Michele
Cavalli, Franco
Luminari, Stefano
Boldorini, Renzo
Mazzucchelli, Luca
Gaidano, Gianluca
Rossi, Davide
Zucca, Emanuele
BLOOD, 2020, 136
[5] REAL-LIFE IMPACT OF THE POD24 INDICATOR IN PATIENTS WITH FOLLICULAR LYMPHOMA
Noguerales Blanca, De Felipe
de Abia Alejandro, Luna
Arribas Ana, Lario
Rumschisky Pablo, Palomo
Jarreta Lucia, Bolea
Palomares Juan, Marquet
Moro Fernando, Martin
Cosio Monica, Garcia
Puente Pilar, Herrera
Francisco Javier, Lopez Jimenez
HAEMATOLOGICA, 2021, 106 (10) : 49 - 49
[6] Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death
Sortais, C.
Lok, A.
Gastinne, T.
Mahe, B.
Dubruille, V.
Blin, N.
Howlett, S.
Tabah, A.
Arnaud, P.
Moreau, A.
Moreau, P.
Leux, C.
Le Gouill, S.
ANNALS OF ONCOLOGY, 2018, 29 : 364 - 364
[7] Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2
Merryman, Reid W.
Belada, David
Sureda, Anna
Leppa, Sirpa
Vermaat, Joost S. P.
Holte, Harald
Hutchings, Martin
Lugtenburg, Pieternella
de Vos, Sven
Abrisqueta, Pau
Nijland, Marcel
Christensen, Jacob Haaber
Wahlin, Bjorn E.
Linton, Kim M.
Wang Liwei
Abbas, Aqeel
Rana, Ali
Quadri, Syed
Falchi, Lorenzo
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S37 - S38
[8] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
Fenghua Gao
Tingting Zhang
Hengqi Liu
Wei Li
Xianming Liu
Lihua Qiu
Lanfang Li
Shiyong Zhou
Zhengzi Qian
Sitong Dong
Sai Zhao
Xianhuo Wang
Huilai Zhang
Annals of Hematology, 2022, 101 : 2383 - 2392
[9] Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis
Gao, Fenghua
Zhang, Tingting
Liu, Hengqi
Li, Wei
Liu, Xianming
Qiu, Lihua
Li, Lanfang
Zhou, Shiyong
Qian, Zhengzi
Dong, Sitong
Zhao, Sai
Wang, Xianhuo
Zhang, Huilai
ANNALS OF HEMATOLOGY, 2022, 101 (11) : 2383 - 2392
[10] Correction to: Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta‑analysis
Fenghua Gao
Tingting Zhang
Hengqi Liu
Wei Li
Xianming Liu
Lihua Qiu
Lanfang Li
Shiyong Zhou
Zhengzi Qian
Sitong Dong
Sai Zhao
Xianhuo Wang
Huilai Zhang
Annals of Hematology, 2022, 101 : 2817 - 2817

← 1 2 3 4 5 →